NCT02106455View on ClinicalTrials.gov

Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -

CompletedOBSERVATIONAL
Enrollment

315

Participants

Timeline

Start Date

August 1, 2008

Primary Completion Date

October 24, 2017

Study Completion Date

October 24, 2017

Conditions
Osseous Paget's Disease
Interventions
DRUG

Sodium risedronate

Sodium risedronate tablets

Trial Locations (2)

Unknown

Osaka

Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY